CRVO CervoMed Inc.
Company Analysis
Latest News
🟢 CervoMed is trading 5% up
CervoMed is trading at $3.17, up +5.13%, after recent development updates, although no specific catalyst was identified for the rise. - On September 28,...
🟢 CervoMed is trading 5.4% up today after FDA removes neflamapimod exposure limit
CervoMed is trading 5.4% higher at $2.82 as of 10:47 a.m. ET on September 29, with its September 28 neflamapimod update the clearest potential catalyst. - The...
CervoMed Announces New Neflamapimod Formulation and Secures FDA Removal of Exposure Limit
CervoMed Inc. announced significant pharmacokinetic, regulatory, and manufacturing updates for its lead drug candidate, neflamapimod. The company has developed...
🟢 CervoMed is trading 5% up today amid a neflamapimod dosing update
CervoMed is trading at $2.67, up 5.12%, amid a neflamapimod dosing update that may be a company-specific catalyst; the release did not explicitly link the move...
🟢 CervoMed is trading 7% up in pre-market with no clear company-specific catalyst
CervoMed is trading at $2.72, up 7.09% in pre-market; no clear company-specific announcement explains the gain. - September 10 company news covered planned...
🟢 CervoMed is trading 5% up today amid broader market strength
CervoMed is trading at $2.53, up 5.18%, during the September 22, 2026 session as broader market strength lifts the Nasdaq Composite 0.51%, supported by easing...
🟢 CervoMed is trading 5% up today amid a broad market rally
CervoMed is trading up 5.33% now at $2.57, broadly moving with September 17, 2026’s risk-on market recovery. - The S&P 500, Nasdaq Composite, and Dow Jones...
🟢 CervoMed is trading 5% up today on broad market strength
CervoMed is trading 5.24% up at $2.61, supported primarily by broad market strength. - The S&P 500, Nasdaq Composite, and Dow Jones are all up more than 1% on...
CervoMed to Present Initial Neflamapimod Phase 2a Trial Data at ISFTD 2026 Conference
CervoMed (CRVO) announced that initial results from its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a...
🔴 CervoMed is trading 5% down today as broader U.S. equities weakened
CervoMed is trading 5.17% down now at $2.57 after broader U.S. equities weakened on August 20, 2026. - The S&P 500, Nasdaq Composite, and Dow Jones were all...
🟢 CervoMed is trading 5.2% up in after-hours trading as healthcare sector rallies
CervoMed is trading 5.15% up now at $2.85 after the broader healthcare sector rallied. - XLV reportedly gained 3.2% on stronger earnings expectations and...
🟢 CervoMed rises 5.8% — Healthcare Stocks Surge on Strong Earnings Outlook and Investor Rotation
With Healthcare (XLV) up 3.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector experienced a significant...
🔴 CervoMed is trading 5% down today with no clear catalyst identified
CervoMed is trading at $2.59, down -5.13%, with no clear company-specific catalyst identified for August 17, 2026. - No new August 17 announcement, earnings...
🟢 CervoMed is trading 5.4% up in pre-market
CervoMed is trading 5.4% up in pre-market at $2.88, rebounding from its August 14 close of $2.73; no new company-specific catalyst was identified. - No new...
🔴 CervoMed is trading 5.87% down today
CervoMed is trading 5.87% down at $2.76, continuing weakness after declining 4.56% to $2.93 on August 13, 2026. - No new company-specific announcement dated...
🟢 CervoMed is trading 6.3% up today in pre-market after flat July PPI reduced Fed hike expectations
CervoMed is trading at $3.11, +6.28% now, as flat July PPI data reduced expectations for a September Federal Reserve rate hike. • Broader risk appetite...
🟢 CervoMed is trading 7.34% up today in after-hours trading as flat July PPI supported rate-hold expectations
CervoMed is trading at $3.15 (+7.34%) in after-hours trading as broader markets strengthened after July PPI was flat, supporting expectations that the Federal...
CervoMed Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
For the second quarter of 2026, analysts anticipate a consensus revenue of $0.05 million and an EPS of -$0.87, while the current price of $2.86 sits...
🟢 CervoMed is trading 11.19% up today after $20.5 million financing extends cash runway
CervoMed is trading 11.19% up at $3.18 after its August 10, 2026 earnings highlighted a $6.6 million quarterly loss and extended cash runway into late 2027...
CervoMed's second quarter 2026 net loss hits $6.6M as cash runway extends into 2027
CervoMed reported a net loss of $6.6 million for the second quarter of 2026, primarily reflecting the transition of its lead candidate neflamapimod toward...